NCT03581916View on ClinicalTrials.gov

A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 11, 2018

Primary Completion Date

November 2, 2018

Study Completion Date

November 2, 2018

Conditions
Healthy
Interventions
DRUG

18F-JNJ-64326067

18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.

Trial Locations (1)

06510

Invicro, New Haven

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03581916 - A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants | Biotech Hunter | Biotech Hunter